Advisors to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer’s drug donanemab.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.